Document Detail


Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials.
MedLine Citation:
PMID:  22891847     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To assess reasons that prevent Alzheimer's disease (AD) patients from being included in clinical trials.
METHODS: In 2009, we reviewed the Lille Memory Clinic's case database to identify patients suitable for inclusion in four AD clinical trials. An initial selection was made on the basis of four criteria: (i) a diagnosis of AD (with or without white matter lesions [WML]), (ii) age, (iii) mini mental state examination (MMSE) score and (iv) symptomatic treatment of AD (cholinesterase inhibitors/memantine). Next, data on patients fulfilling these criteria were reviewed against all the inclusion/exclusion criteria for four clinical trials performed in 2009 at the Memory Clinic. Reasons for non-inclusion were analyzed.
RESULTS: Two hundred and five patients were selected according to the four initial criteria. Reasons for subsequently not including some of patients in clinical trials were abnormalities on MRI (56.9%, 88.9% of which were WML), unauthorized medication (37.3%), the lack of a study partner/informant (37.1%), the presence of a non-authorized disease (24.4%), contraindication to MRI (9%), a change in diagnosis over time (3.9%), visual/auditory impairments (2.9%), alcohol abuse (2%) and an insufficient educational level (1%).
CONCLUSION: A high proportion of AD patients presented with vascular abnormalities on MRI. This was not unexpected, since the patients were selected from the database and, as shown in epidemiologic studies, cerebrovascular diseases are frequently associated with AD. The presence of a study partner is essential for enabling a patient to participate in clinical trials because of the need to record reliably primary and secondary outcomes.
Authors:
Adeline Rollin-Sillaire; Laetitia Breuilh; Julia Salleron; Stéphanie Bombois; Pascaline Cassagnaud; Vincent Deramecourt; Marie-Anne Mackowiak; Florence Pasquier
Related Documents :
6972697 - Effect of antipyretics on the length of hospital stay of pediatric patients with bacter...
9347577 - Severe chronic neutropenia: pathophysiology and therapy.
12729347 - Multidrug-resistant tuberculous meningitis in patients with aids.
9361057 - Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
23260467 - Severe sepsis in do-not-resuscitate patients: intervention and mortality rates.
20864497 - Safe and successful treatment of intravenous drug users with a peripherally inserted ce...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  75     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-18     Completed Date:  2013-09-20     Revised Date:  2014-04-01    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1089-97     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alzheimer Disease / diagnosis*
Double-Blind Method
Humans
Middle Aged
Patient Selection*
Randomized Controlled Trials as Topic / standards*
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human alpha-actinin-3 genotype association with exercise-induced muscle damage and the repeated-bout...
Next Document:  Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease morta...